Atypical hyperplasia of the breast


Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Causes

By Mayo Clinic staff

CLICK TO ENLARGE

Illustration showing how cancer develops 
How cancer develops

Living With Cancer

Subscribe to our Living With Cancer e-newsletter to stay up to date on cancer topics.

Sign up now

It's not clear what causes atypical hyperplasia. Atypical hyperplasia forms when breast cells become abnormal in number, size, shape, growth pattern and appearance. Location of the abnormal cells within the breast tissue — the lobules or the milk ducts — determines whether the cells are atypical lobular hyperplasia or atypical ductal hyperplasia.

Atypical hyperplasia is thought to be part of the complex, multistep process by which breast cancer develops. The process begins when normal cell development and growth become disrupted, causing an overproduction of normal-looking cells (hyperplasia). Atypical hyperplasia occurs when the excess cells stack upon one another and begin to take on an abnormal appearance. The abnormal cells can continue to change in appearance and multiply, evolving into noninvasive (in situ) cancer, in which cancer cells remain confined to the area where they start growing. Left untreated, the cancer cells may eventually become invasive cancer, invading surrounding tissue, blood vessels or lymph channels.

References
  1. Lester SC. The breast. In: Kumar V, et al. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia, Pa.: Saunders Elsevier; 2010. http://www.mdconsult.com/books/about.do?about=true&eid=4-u1.0-B978-1-4377-0792-2..X5001-9&isbn=978-1-4377-0792-2&uniqId=273803839-4. Accessed Aug. 17, 2011.
  2. Bombonati A, et al. The molecular pathology of breast cancer progression. Journal of Pathology. 2011;223:307.
  3. Hartmann LC, et al. Benign breast disease and the risk of breast cancer. The New England Journal of Medicine. 2005;353:229.
  4. London SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. Journal of the American Medical Association. 1992;267:941.
  5. Degnim AC, et al. Stratification of breast cancer risk in women with atypia: A Mayo cohort study. Journal of Clinical Oncology. 2007;25:2671.
  6. Dupont WD, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258.
  7. Breast cancer risk reduction. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Aug. 17, 2011.
  8. Breast cancer screening and diagnosis. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Aug. 17, 2011.
  9. Pruthi S (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 31, 2011.
  10. Goss PE, et al. Exemestane for breast-cancer prevention in postmenopausal women. The New England Journal of Medicine. 2011;25:2381.
DS01018 Oct. 1, 2011

© 1998-2013 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

  • Reprints
  • Print
  • Share on:

  • Email

Advertisement


Text Size: smaller largerlarger